Description of B Lymphocytes and Plasma Cells, Complement, and Chemokines/receptors in Acute Liver Allograft Rejection
Overview
Authors
Affiliations
Background: Although antibody mechanisms play a pathogenetic role in liver allograft rejection, no data exist on B lymphocytes, plasma cells, complement, and chemokines in rejected liver tissue.
Methods: Liver biopsy specimens from 25 patients with acute allograft rejection (AR) (rejection activity index, RAI score: 1-9) were analyzed by immunohistochemistry (IH) and reverse transcriptase-polymerase chain reaction (RT-PCR) and compared with biopsy specimens taken prior to implantation (PI). The number of CD20 and CD138 cells was evaluated, and the presence and abundance of the chemokines macrophage inflammatory protein (MIP)-3alpha, CXCL9, CXCL10, CXCL11, CXCL12, and their receptors CCR-6, CXCR3, and CXCR4 were examined. Complement depositions were visualized by C4d IH.
Results: The numbers of B lymphocytes (P=0.002) and plasma cells (P=0.022) were significantly higher in AR biopsy specimens compared with PI biopsy specimens. MIP-3alpha and CCR-6 cells were detected in the portal fields of all AR biopsy specimens. IH double staining revealed a colocalization of MIP-3alpha/CD20 cells; C4d deposits could be demonstrated along the portal capillaries. All examined chemokines and receptors could be detected in normal liver tissue and in AR biopsy specimens by RT-PCR and semiquantitative RT-PCR, demonstrating an overexpression of CXCL10 and -11.
Conclusions: The significant increase of B lymphocytes and plasma cells during acute rejection, together with the lack of a significant increase of proliferating cells, indicates that the migration of B lymphocytes and plasma cells-promoted by the expression of B-cell activating chemokines/receptors-plays a key role in acute liver rejection. The C4d deposits along the portal capillaries indicate a humorally mediated alloresponse caused by the accumulated B and plasma cells.
Cicalese L, Walton Z, Du X, Kulkarni R, Qiu S, Hag M Transpl Int. 2024; 37:13232.
PMID: 39267618 PMC: 11391112. DOI: 10.3389/ti.2024.13232.
Immune Cell Trafficking to the Liver.
Chaudhry S, Emond J, Griesemer A Transplantation. 2019; 103(7):1323-1337.
PMID: 30817405 PMC: 7044802. DOI: 10.1097/TP.0000000000002690.
Alsughayyir J, Pettigrew G, Motallebzadeh R Front Immunol. 2017; 8:1639.
PMID: 29218052 PMC: 5703719. DOI: 10.3389/fimmu.2017.01639.
Clinical significance of donor-specific human leukocyte antigen antibodies in liver transplantation.
Cuadrado A, San Segundo D, Lopez-Hoyos M, Crespo J, Fabrega E World J Gastroenterol. 2015; 21(39):11016-26.
PMID: 26494958 PMC: 4607901. DOI: 10.3748/wjg.v21.i39.11016.
ABO-compatible liver allograft antibody-mediated rejection: an update.
Demetris A, Zeevi A, OLeary J Curr Opin Organ Transplant. 2015; 20(3):314-24.
PMID: 25944231 PMC: 4646419. DOI: 10.1097/MOT.0000000000000194.